Want to see FDMT full AI Analyst Report?
FDMT Stock Chart & Stats
$10.07
$0.31(3.08%)
At close: 4:00 PM EDT
$10.07
$0.31(3.08%)
Day’s Range― - ―
52-Week Range$4.30 - $14.00
Previous Close$10.76
Volume531.42K
Average Volume (3M)968.42K
Market Cap
$502.37M
Enterprise Value$263.32
Total Cash (Recent Filing)$390.89M
Total Debt (Recent Filing)$20.54M
Price to Earnings (P/E)―
Beta0.73
Next Earnings
Aug 06, 2026EPS Estimate
-1.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.66
Shares Outstanding52,276,253
10 Day Avg. Volume698,244
30 Day Avg. Volume968,420
Financial Highlights & Ratios
PEG Ratio0.16
Price to Book (P/B)0.86
Price to Sales (P/S)5.10
P/FCF Ratio-3.98
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$30.33Price Target Upside201.22% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering7
EPS Forecast (FY)-4.04
Revenue Forecast (FY)$12.23M
Bulls Say, Bears Say
Bulls Say
Proprietary AAV Vector Platform4D's engineered AAV capsid platform is a durable competitive asset: tissue-targeted delivery is central to gene therapy success, enabling differentiated programs and licensing. A robust platform supports repeat collaborations, IP value, and long-term revenue potential beyond any single program.
Durable Phase 2b PRISM Efficacy And SafetyTwo‑year PRISM results materially de‑risk 4D‑150: sustained vision outcomes, major reduction in treatment burden, and a consistent safety profile support the planned Phase 3 dose. Those durable clinical readouts strengthen regulatory rationale and commercial differentiation versus incumbent biologics.
Extended Runway Via $200M Secured Loan FacilityThe up-to-$200M facility meaningfully improves near-to-medium term funding optionality, reducing immediate reliance on equity raises. While secured and covenanted, the tranche structure ties funding to program milestones, aligning capital availability with development progress and enabling completion of late‑stage work.
Bears Say
Sustained Negative Operating And Free Cash FlowPersistent high cash burn is a structural risk: ongoing negative operating and free cash flow require recurrent external financing or debt, increasing dilution or leverage. Even with recent financing, sustained cash outflows can strain runway and force tradeoffs in program prioritization over the next several quarters.
Large Operating Losses And Negative Gross ProfitNegative gross profit and outsized operating losses indicate product economics are unproven and margins are unstable. Until commercialization or sustained licensing revenue, the company will continue to erode equity and report negative returns, limiting internal funding capacity and raising dependency on partners or markets.
Revenue Volatility From Milestone-dependent ModelReliance on milestone and collaboration payments creates uneven revenue recognition and forecasting difficulty. The 2025 revenue spike followed by a TTM decline highlights this structural volatility, complicating cash planning and increasing the probability of dilutive financings if milestone timing slips.
4D Molecular Therapeutics News
FDMT FAQ
What was 4D Molecular Therapeutics’s price range in the past 12 months?
4D Molecular Therapeutics lowest stock price was $4.30 and its highest was $14.00 in the past 12 months.
What is 4D Molecular Therapeutics’s market cap?
4D Molecular Therapeutics’s market cap is $502.37M.
When is 4D Molecular Therapeutics’s upcoming earnings report date?
4D Molecular Therapeutics’s upcoming earnings report date is Aug 06, 2026 which is in 6 days.
How were 4D Molecular Therapeutics’s earnings last quarter?
4D Molecular Therapeutics released its earnings results on May 07, 2026. The company reported -$1.01 earnings per share for the quarter, missing the consensus estimate of -$0.996 by -$0.014.
Is 4D Molecular Therapeutics overvalued?
According to Wall Street analysts 4D Molecular Therapeutics’s price is currently Undervalued.
Does 4D Molecular Therapeutics pay dividends?
4D Molecular Therapeutics does not currently pay dividends.
What is 4D Molecular Therapeutics’s EPS estimate?
4D Molecular Therapeutics’s EPS estimate is -1.02.
How many shares outstanding does 4D Molecular Therapeutics have?
4D Molecular Therapeutics has 52,276,253 shares outstanding.
What happened to 4D Molecular Therapeutics’s price movement after its last earnings report?
4D Molecular Therapeutics reported an EPS of -$1.01 in its last earnings report, missing expectations of -$0.996. Following the earnings report the stock price went up 2.115%.
Which hedge fund is a major shareholder of 4D Molecular Therapeutics?
Currently, no hedge funds are holding shares in FDMT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
4D Molecular Therapeutics Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$30.33 (201.22% Upside)
$30.33 (201.22% Upside)
Blogger Sentiment
Bullish
FDMT Sentiment 100%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 1.1M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $117.7K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Negative
Last 7 Days ▼ 1.1%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
Technicals
SMA
Positive
20 days / 200 days
Momentum
118.43%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-0.55%
Trailing 12-Months
Company Description
4D Molecular Therapeutics
4D Molecular Therapeutics, Inc. is a clinical-stage gene therapy company that engineers therapeutic agents by leveraging its proprietary adeno-associated virus (AAV) vector technology. The company's developmental efforts are concentrated across a trio of therapeutic fields: ophthalmology (eye conditions), cardiology (heart ailments), and pulmonology (respiratory disorders). Within its active pipeline, three specific product candidates have advanced into clinical trial phases, all currently undergoing Phase 1/2 clinical assessment: 4D-125 is being evaluated for the treatment of X-linked retinitis pigmentosa. 4D-110 targets choroideremia. 4D-310 is focused on addressing Fabry disease. Beyond these, two Investigational New Drug (IND) candidates are in development: 4D-150, aimed at combating wet age-related macular degeneration, and 4D-710, designed to tackle cystic fibrosis lung disease. To advance its mission, 4D Molecular Therapeutics, Inc. actively engages in research and development partnerships with entities such as uniQure, CRF, Roche, and CFF. The firm commenced operations in 2013 and maintains its headquarters in Emeryville, California.
FDMT Stock 12 Month Forecast
Average Price Target
$30.33
▲(201.22% Upside)
Technical Analysis
Assembly Biosciences
―
Korro Bio
―
Design Therapeutics
―
Immuneering
―
Aura Biosciences Inc
―
Ownership Overview
2.18% Insiders
13.18% Mutual Funds
0.32% Other Institutional Investors
65.81% Public Companies and
Individual Investors